Wedbush Downgrades Sionna Therapeutics to Neutral, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Negative 93.7%

Neg 93.7% Neu 0% Pos 0%

Wedbush analyst Laura Chico downgrades Sionna Therapeutics (NASDAQ:SION) from Outperform to Neutral and lowers the price target from $53 to $5.